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Abstract
Background
Financial incentives promote many health behaviors, but effective ways to deliver health incentives
remain uncertain.
Methods
We randomly assigned CVS Caremark employees and their relatives and friends to one of four incentive
programs or to usual care for smoking cessation. Two of the incentive programs targeted individuals, and
two targeted groups of six participants. One of the individual-oriented programs and one of the grouporiented programs entailed rewards of approximately $800 for smoking cessation; the others entailed
refundable deposits of $150 plus $650 in reward payments for successful participants. Usual care
included informational resources and free smoking-cessation aids.
Results
Overall, 2538 participants were enrolled. Of those assigned to reward-based programs, 90.0% accepted
this assignment, as compared with 13.7% of those assigned to deposit-based programs (P
Conclusions
Reward-based programs were much more commonly accepted than deposit-based programs, leading to
higher rates of sustained abstinence from smoking. Group-oriented incentive programs were no more
effective than individual-oriented programs.
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Financial incentives promote many health behaviors, but effective ways to deliver
health incentives remain uncertain.
METHODS

We randomly assigned CVS Caremark employees and their relatives and friends to
one of four incentive programs or to usual care for smoking cessation. Two of the
incentive programs targeted individuals, and two targeted groups of six participants. One of the individual-oriented programs and one of the group-oriented
programs entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposits of $150 plus $650 in reward payments for successful participants. Usual care included informational resources and free smokingcessation aids.
RESULTS

Overall, 2538 participants were enrolled. Of those assigned to reward-based programs, 90.0% accepted the assignment, as compared with 13.7% of those assigned
to deposit-based programs (P<0.001). In intention-to-treat analyses, rates of sustained abstinence from smoking through 6 months were higher with each of the
four incentive programs (range, 9.4 to 16.0%) than with usual care (6.0%) (P<0.05
for all comparisons); the superiority of reward-based programs was sustained
through 12 months. Group-oriented and individual-oriented programs were associated with similar 6-month abstinence rates (13.7% and 12.1%, respectively;
P = 0.29). Reward-based programs were associated with higher abstinence rates
than deposit-based programs (15.7% vs. 10.2%, P<0.001). However, in instrumental-variable analyses that accounted for differential acceptance, the rate of abstinence at 6 months was 13.2 percentage points (95% confidence interval, 3.1 to
22.8) higher in the deposit-based programs than in the reward-based programs
among the estimated 13.7% of the participants who would accept participation in
either type of program.
CONCLUSIONS

Reward-based programs were much more commonly accepted than deposit-based
programs, leading to higher rates of sustained abstinence from smoking. Grouporiented incentive programs were no more effective than individual-oriented
programs. (Funded by the National Institutes of Health and CVS Caremark;
ClinicalTrials.gov number, NCT01526265.)
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F

inancial incentives have been shown
to promote a variety of health behaviors.1-8
For example, in a randomized, clinical
trial involving 878 General Electric employees, a
bundle of incentives worth $750 for smoking
cessation nearly tripled quit rates, from 5.0% to
14.7%,8 and led to a program adapted by General Electric for its U.S. employees.9 Although incentive programs are increasingly used by governments, employers, and insurers to motivate
changes in health behavior,10,11 their design is
usually based on the traditional economic assumption that the size of the incentive determines its effectiveness. In contrast, behavioral
economic theory suggests that incentives of
similar size may have very different effects depending on how they are designed.12
For example, deposit or “commitment” contracts, whereby participants put some of their
own money at risk and recoup it if they are successful in changing their behavior, have been
used in a variety of online and employer-based
behavioral-change programs. Because people are
typically more motivated to avoid losses than to
seek gains,13 deposit contracts should be more
successful than reward programs. However, the
need to make deposits may deter people from
participating, and the overall effectiveness of
deposit and reward programs has not been compared.14,15
Furthermore, incentives that target groups
may be more effective than incentives that target
individuals because people are strongly motivated
by social comparisons.16-18 Collaborative incentives, whereby payments to successful group
members increase with the overall success of the
group, may add dimensions of interpersonal accountability and teamwork.19 Competitive designs, such as pari-mutuel schemes in which
money deposited by group members who do not
change their behavior gets distributed to group
members who do, may amplify peoples’ aversions to loss by highlighting the regret they
may feel if others benefit from their failure to
change.20,21
We therefore evaluated incentive programs
for smoking cessation that are based on rewards or deposit contracts and that are delivered at the individual or group level, comparing
the interventions on three measures: acceptance, defined as the proportion of people who
accept the incentive program when offered;
n engl j med 372;22

overall effectiveness, assessed as the proportion
of people offered each program who stop smoking; and efficacy, assessed as the proportion of
people who stop smoking if they accept a given
incentive program.

A Quick Take
summary is
available at
NEJM.org

Me thods
Trial Design

We conducted a five-group randomized, controlled trial comparing usual care with four incentive programs aimed at promoting sustained
abstinence from smoking. The protocol (available with the full text of this article at NEJM.org)
was approved by the institutional review board
at the University of Pennsylvania. The first author vouches for the accuracy and completeness
of the data and for the fidelity of the study to the
protocol.
Study Population

We used a multifaceted recruitment scheme
(Fig. S1 in the Supplementary Appendix, available at NEJM.org) to enroll CVS Caremark employees or their relatives and friends across the
United States. Eligible participants were at least
18 years of age, reported smoking at least 5 cigarettes per day, had Internet access, and indicated an interest in learning about ways to stop
smoking. Recruitment occurred from February
2012 through October 2012. Using the Way to
Health Web-based research portal created for
this and other studies,22 participants opened an
account, electronically signed the informedconsent document, and completed a baseline
questionnaire. Participants were told that they
would be paid for completing questionnaires
and submitting samples to confirm smoking
abstinence and that the study tested different
ways of providing financial incentives to promote cessation. To dissuade nonsmokers from
enrolling, we also informed potential participants
that we would randomly screen for baseline
smoking.
After randomization, participants learned the
details of their assigned intervention, were asked
to accept or decline their intervention, and chose
a target quit date between 1 and 90 days after
enrollment. We then selected a random sample
of 5% of these enrolled participants to undergo
baseline cotinine screening and offered $100 for
completing a cotinine assay.
nejm.org
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4629 Persons created Way to Health
account
612 Were excluded
10 Were <18 yr of age
84 Smoked <5 cigarettes/day
54 Smoked <6 mo
38 Did not have Internet access
426 Were not CVS Caremark
employees or their relatives
or friends
4017 Were eligible

1479 Did not complete enrollment
52 Did not provide consent
55 Would not give Social
Security number
1372 Did not complete baseline
survey

2538 Underwent randomization

468 Were assigned
to usual care

498 Were assigned
to individual reward

519 Were assigned to
collaborative reward

582 Were assigned to
individual deposit

471 Were assigned to
competitive deposit

468 Were included
in primary analysis

498 Were included
in primary analysis

519 Were included
in primary analysis

582 Were included
in primary analysis

471 Were included
in primary analysis

Figure 1. Assessment for Eligibility and Randomization.

Randomization and Interventions

Participants were randomly assigned on an individual basis to one of five groups (Fig. 1). Randomization was stratified according to two dichotomous variables: whether participants had
full health care benefits through CVS Caremark
and whether their annual household income was
at least $60,000 (the CVS Caremark workforce
median) or less than $60,000. We developed an
adaptive randomization algorithm23-26 that updated the assignment probabilities to the five
groups after every third enrolled participant.
Updated probabilities reflected the inverse of the
proportion of participants assigned to that group
who accepted the intervention, relative to total
acceptance across groups.26 This approach balances recruitment of accepting participants
across groups by increasing the odds of randomization to interventions that previous participants
declined.
2110

n engl j med 372;22

All the participants were offered usual care,
consisting of information about local smokingcessation resources, cessation guides produced by
the American Cancer Society, and, for the 41% of
the participants receiving health benefits through
CVS Caremark, free access to a behavioral-modification program and nicotine-replacement therapy.
Participants assigned to the two individual-incentive groups were also eligible to receive $200 if
they had biochemically confirmed abstinence
at each of three times: 14 days, 30 days, and
6 months after their target quit dates. Participants
would get an additional $200 bonus at 6 months,
for a total of $800 (Fig. S2 in the Supplementary
Appendix). In the individual-deposit group, this
sum included a $150 deposit that would be refunded to participants who quit smoking.
In the collaborative-reward and competitivedeposit groups, cohorts of six smokers each were
formed on a rolling basis, linking participants
nejm.org
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who selected quit dates nearest each other. In the
collaborative-reward group, payments to successful group members at each time point increased
with increasing group success rates, from $100
per time point if one participant quit to $600 per
time point per participant if all six quit. We
sought to foster collaboration among participants
with the use of a Web-based chat room through
which they could communicate throughout the
study.
In the competitive-deposit group, $150 deposits from each of six group members, plus a $450
matching reward per member ($3,600 total), was
redistributed among members who quit at each
time point. For example, if only two participants
in a group quit at 14 days but returned to smoking by 30 days, those two participants would
receive $600 each at 14 days, and there would be
no further payouts to the members of that group.
Members of competitive cohorts received accurate but anonymous descriptions of their competitors to make vivid the possibility that others
might benefit from their own lack of change21
without enabling participants to undermine a
competitor’s efforts.
Participants in the group-incentive groups
were also given a $200 bonus if they sustained
abstinence through 6 months. Thus, the four
interventions differed in how incentives would
accrue and be disbursed (Fig. S2 in the Supplementary Appendix), but the payment schedule
and bonus were identical, and on the basis of
anticipated success rates, we estimated that each
intervention carried an expected value of $800.
Outcomes

The primary outcome was sustained abstinence
from smoking for 6 months after the target quit
date.27 Achievement of sustained abstinence required that submitted saliva samples had a cotinine concentration of less than 10 ng per milliliter28 at 14 days, 30 days, and 6 months. For
users of nicotine-replacement therapy, a urinary
sample with an anabasine concentration of less
than 3 ng per milliliter was considered to show
sustained abstinence.29 Participants who did not
submit samples were coded as actively smoking.
Secondary outcomes included the initial quit
rate at 14 days, sustained abstinence for 30 days,
and sustained abstinence through 12 months
(i.e., 6 months after the final incentive disbursement).
n engl j med 372;22

Incentive acceptance rates reflected the proportion of participants assigned to that incentive
who agreed to the contract. In the two groups
requiring deposits, we considered participants to
have accepted the intervention if they made $150
deposits by credit or debit card within 60 days
after enrollment or before their selected quit
date, whichever came first. Consenting participants who declined their assigned program
remained in their assigned group for intentionto-treat analyses and were treated identically to
those in the usual-care group.
Statistical Analysis

We specified three analyses corresponding to
the aims of the study. First, we used logistic regression to compare acceptance of the interventions, adjusting for the two variables according
to which the randomization was stratified.30 Second, we conducted intention-to-treat analyses
using logistic regression to compare the effectiveness of incentive programs among all randomly assigned participants. Third, we compared the efficacy of the interventions. We first
conducted traditional per-protocol analyses, comparing groups of participants who accepted different interventions. However, because such
analyses are subject to selection biases,31 our
primary approach to measure efficacy modeled
the randomization group as an instrumental
variable32,33 in analyses of the complier average
treatment effect.34-36 These analyses, described in
detail in the Supplementary Appendix, used data
on all randomly assigned participants to estimate
treatment effects for participants who would have
accepted each intervention.
We estimated that a sample of 2185 participants would provide 80% power to detect absolute differences of at least 7.5 percentage points
in the rate of sustained abstinence between any
one of the three novel incentive programs and
the individual-reward program. Details of this
calculation are provided in the Supplementary
Appendix.

R e sult s
Patient Characteristics

Overall, 2538 participants were enrolled. The
demographic and smoking-related characteristics
of the participants were balanced across the five
study groups (Table 1).
nejm.org
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Table 1. Participant Characteristics (Intention-to-Treat Population).*

Characteristic

Usual Care
(N = 468)

Individual
Reward
(N = 498)

Collaborative
Reward
(N = 519)

Individual
Deposit
(N = 582)

Competitive
Deposit
(N = 471)

34

32

32

33

33

Demographic characteristics
Age — yr
Median
Interquartile range
Female sex — no. (%)

26–47

25–46

25–45

25–48

25–45

300 (64)

312 (63)

322 (62)

367 (63)

293 (62)

365 (78)

409 (82)

387 (75)

452 (78)

376 (80)

Race — no. (%)†
White
Black

43 (9)

44 (9)

58 (11)

54 (9)

49 (10)

Other

60 (13)

45 (9)

74 (14)

76 (13)

46 (10)

Years of education‡
Median

13

13

13

13

13

12–14

12–14

12–15

12–15

12–15

<$60,000

346 (74)

375 (75)

382 (74)

403 (69)

358 (76)

≥$60,000

122 (26)

123 (25)

137 (26)

179 (31)

113 (24)

Enrolled in CVS Caremark health care plan

152 (32)

174 (35)

177 (34)

213 (37)

168 (36)

Not enrolled in CVS Caremark health care plan

139 (30)

136 (27)

151 (29)

180 (31)

146 (31)

36 (8)

33 (7)

26 (5)

29 (5)

36 (8)

141 (30)

155 (31)

165 (32)

160 (27)

121 (26)

15

15

15

15

15

10–20

10–20

9–20

10–20

10–20

Interquartile range
Annual household income — no. (%)

Health insurance — no. (%)§
CVS Caremark employee

Relative or friend of CVS Caremark employee
Enrolled in CVS Caremark health care plan
Not enrolled in CVS Caremark health care plan
Smoking history
No. of cigarettes smoked per day
Median
Interquartile range
Duration of regular smoking — yr
Median
Interquartile range

15

12

13

14

14

6–26

6–25

6–25

6–25

7–25

17

17

17

17

17

15–19

15–19

15–19

15–19

15–19

101 (22)

111 (22)

118 (23)

122 (21)

95 (20)

Age at first smoking — yr
Median
Interquartile range
Level of nicotine dependence — no. (%)¶
Low
Low to moderate

148 (32)

155 (31)

152 (29)

185 (32)

141 (30)

Moderate

194 (41)

210 (42)

229 (44)

251 (43)

215 (46)

25 (5)

22 (4)

20 (4)

24 (4)

20 (4)

High
Stage of change — no. (%)‖
Preparation

300 (64)

312 (63)

327 (63)

372 (64)

312 (66)

Contemplation

168 (36)

186 (37)

192 (37)

210 (36)

158 (34)

300 (64)

307 (62)

328 (63)

361 (62)

294 (62)

Successfully quit for a 24-hr period in past year — no. (%)

2112
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Table 1. (Continued.)
Usual Care
(N = 468)

Individual
Reward
(N = 498)

Collaborative
Reward
(N = 519)

Individual
Deposit
(N = 582)

Competitive
Deposit
(N = 471)

Ever used NRT or assistance to quit smoking — no. (%)

340 (73)

384 (77)

384 (74)

421 (72)

350 (74)

Currently using other methods to quit smoking — no. (%)**

65 (14)

51 (10)

71 (14)

73 (13)

47 (10)

Characteristic

*	The intention-to-treat population includes all participants who underwent randomization to the five study groups. There were no sig
nificant differences between the study groups in any of the baseline characteristics listed (P>0.05). NRT denotes nicotine-replacement
therapy.
†	Race was self-reported.
‡	Years of education range from grade 1 to 17, with 17 representing “at least some graduate school” and 13 to 16 representing 1 to 4 years
of college.
§	The CVS Caremark health care plan includes free access to a behavioral-modification program and NRT.
¶	The level of dependence is based on the score on the Fagerström Test for Nicotine Dependence. Scores range from 1 to 10, with higher
scores indicating a more intense physical dependence on nicotine. Low dependence corresponds to a score of 1 or 2, low-to-moderate dependence a score of 3 or 4, moderate dependence a score of 5 to 7, and high dependence a score of 8 to 10.
‖	The participants were asked, “Are you seriously thinking of quitting smoking?” and were given three options to select: yes, within the next
30 days (preparation stage); yes, within the next 6 months (contemplation stage); or no, not thinking of quitting (precontemplation
stage). The values for contemplation stage include 10 participants in the precontemplation stage: 2 participants in the usual-care group,
2 participants in the individual-reward group, 2 participants in the collaborative-reward group, 3 participants in the individual-deposit group,
and 1 participant in the competitive-deposit group. Data were missing for 1 participant in the competitive-deposit group.
**	Participant is currently using NRT, behavioral therapy, prescription medication, or other method to quit smoking.

Acceptance of Interventions

Of 2070 participants assigned to one of the four
intervention groups, 1060 (51.2%) accepted that
intervention. Participants were much more likely
to accept the two reward-based incentive programs (combined acceptance rate, 90.0%) than
the two deposit-based programs (combined acceptance rate, 13.7%) (P<0.001) (Fig. 2). Participants were similarly likely to accept the individual incentives (combined acceptance rate, 50.6%)
and the group incentives (combined acceptance
rate, 51.9%) (P = 0.55).
Effectiveness and Costs of Interventions

than at 30 days or 6 months in all groups (Table
S3 in the Supplementary Appendix). In secondary
analyses of self-reported abstinence at 12 months,
relapsed smoking was much less common than
in analyses requiring biochemical confirmation,
and all incentive groups remained superior to
usual care (Table S2 in the Supplementary Appendix).
At 6 months, the proportion of participants
with sustained abstinence was greater with reward-based incentives (15.7%) than with depositbased incentives (10.2%) (P<0.001) (Table S4 in
the Supplementary Appendix) and was similar
between participants assigned to individual-
incentive programs and those assigned to groupincentive programs (12.1% vs. 13.7%, P = 0.29)
(Table S5 in the Supplementary Appendix). Participants with access to free pharmacologic cessation aids through their CVS Caremark benefits
did not have higher abstinence rates than participants without such benefits (Table S6 in the
Supplementary Appendix). Total costs spent per
participant who had sustained abstinence were
lower in the deposit-based groups than in the
reward-based groups (Fig. S3 in the Supplementary Appendix).

Median payouts to participants who stopped smoking in the four incentive groups were similar
(Table S1 in the Supplementary Appendix). In
intention-to-treat analyses, all four programs
yielded greater rates of sustained abstinence
from smoking through 6 months (range, 9.4 to
16.0%) than did usual care (6.0%) (P<0.05 for all
comparisons) (Fig. 3, and Table S2 in the Supplementary Appendix). At 12 months (6 months after
the cessation of incentives), roughly half the participants who were abstinent through 6 months
in all groups submitted negative cotinine assays,
and only the reward-based incentive programs
remained superior to usual care (Fig. 3). The Efficacy of Interventions
proportion of self-reported quitters who submit- Given the similar effectiveness of individual reted a cotinine sample was lower at 12 months wards and collaborative rewards and of individn engl j med 372;22
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85.3

80
70
60
50
40
30
20

12.6

15.1

Individual
deposit
(75/582)

Competitive
deposit
(71/471)

10
0

Individual
reward
(472/498)

Collaborative
reward
(442/519)

Assigned Intervention

Figure 2. Acceptance Rates of Financial-Incentive Structures.
Acceptance rates were adjusted for two stratifying variables30: whether participants received their health insurance through CVS Caremark and whether
their annual household income was at least $60,000 or less than $60,000.
I bars denote 95% confidence intervals. In parentheses, the numerator indicates the number of participants accepting each intervention, and the denominator indicates the number of participants assigned to each intervention.
The usual-care group is not shown, because there was no option to decline
usual care.

ual deposits and competitive deposits, we grouped
the reward-based incentives as well as the deposit-based incentives for efficacy analyses. In
standard per-protocol analyses, 52.3% of those
who accepted deposits versus 17.1% of those who
accepted rewards had sustained abstinence through
6 months (P<0.001), and similarly large differences were observed at all time points (Table S7
in the Supplementary Appendix). In analyses of
the complier average treatment effect, which adjust for the selection effects inherent in per-protocol analyses, the rate of abstinence at 6 months
was 13.2 percentage points (95% confidence interval, 3.1 to 22.8) higher in the deposit-based
programs than in the reward-based programs
among the 13.7% of smokers who would accept
either type of incentive (Table 2). According to
this approach, deposits were superior to rewards
even if we assumed that participants who would
accept deposits had up to 12.5 times greater
underlying propensities to stop smoking than
participants who would accept rewards only.

2114
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Analyses Accounting for Enrollment
of Potential Nonsmokers

94.8

90

of

n engl j med 372;22

Among 150 participants asked to submit a cotinine assay at baseline to confirm smoking status, 9 (6.0%) submitted negative assays and 21
(14.0%) did not return assays. These rates were
similar across groups (Table S8 in the Supplementary Appendix), and sensitivity analyses adjusting for the possibility that up to 20% of the
participants were not smokers revealed nearly
identical estimates of effectiveness (Table S9 in
the Supplementary Appendix).

Discussion
More than 50 years after the release of the first
Surgeon General’s report on the harmful effects
of smoking, national policies, behavioral programs, and pharmacologic approaches have helped
reduce smoking rates in the United States.37
However, the need for new approaches is clear
because smoking remains the leading cause of
preventable illness and death.38,39
In this large randomized trial across the
United States, we found that four different incentive programs with expected values of $800
were each effective in promoting sustained abstinence from smoking. Perhaps the most important finding is that incentive programs that
required people to deposit $150 of their own
money were less effective overall than rewardbased programs of similar value because few
people accepted such deposit programs. This was
true despite the $650 reward offered to depositarm participants in addition to the return of their
original $150 deposits. However, analyses that
account for the different acceptance rates of the
interventions showed that deposit-based incentives were substantially more efficacious than
reward-based incentives among people who would
have accepted either. The robustness of this result
to reasonably large potential selection effects suggests that incentives that build on participants’
loss aversion13 may meaningfully change behavior.
Second, we found that group-oriented reward
programs were not significantly more effective
than individual-oriented programs. The results
of this large trial are therefore consistent with
those of small randomized, controlled trials of
incentives for weight loss in which group-oriented

nejm.org

May 28, 2015

The New England Journal of Medicine
Downloaded from nejm.org at UNIV OF PENN LIBRARY on July 18, 2017. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

Financial-Incentive Progr ams for Smoking Cessation

n engl j med 372;22

Randomization Group
Usual care

Individual
reward

20

Sustained Abstinence (% of participants)

payments, as compared with individual-oriented
payments, produced small early benefits that
were not sustained over time.19,22
Finally, the finding that individual rewards of
$800, as compared with usual care, nearly tripled the rate of smoking cessation among CVS
Caremark employees and their friends and family confirms and extends the generalizability of
our finding from a previous trial involving General Electric employees.8 In addition to the public health effects of such smoking reductions,
these findings are important for employers. Because employing a smoker is estimated to cost
$5,816 more each year than employing a nonsmoker,40 even an $800 payment borne entirely
by employers and paid only to those who quit
would be highly cost-saving.
This study has limitations. First, the low rate
of acceptance of the deposit programs required
protocol modifications to restrict the proportions of participants who would be randomly
assigned to those groups. Implementing these
limitations preserved balance in participant characteristics across groups and preserved power
for all effectiveness analyses but limited the
precision of analyses comparing the efficacy of
reward and deposit groups. Second, only 41% of
the participants had access to free pharmacologic and behavioral cessation aids through their
employee benefits. However, smoking-cessation
rates were not higher among those with access
to such aids, a finding that suggests that the
superiority of incentives would hold in populations with universal access. Third, in all trial
groups, nearly half the smokers who quit at the
end of the intervention at 6 months did not
document sustained abstinence through 12
months. This suggests similar durability of financial incentives to nicotine-replacement therapy and bupropion, for which relapse after
completion of treatment has also occurred in
roughly 50% of the participants.41,42 Secondary
analyses suggest that the true relapse rates in
our trial may have been lower, given the reduction in submission of any samples at 12 months
across groups (Table S3 in the Supplementary
Appendix).
This study also has several strengths. In addition to comparing financial incentives for
smoking cessation in a large number of partici-
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Figure 3. Rates of Sustained Abstinence from Smoking at 6 and 12 Months
after Target Quit Date.
The primary outcome was sustained abstinence through 6 months. Asterisks indicate P values (* for P<0.05, ** for P<0.01, and *** for P<0.001) for
the comparison of the four intervention groups to usual care, with adjustment for the two stratifying variables30: whether participants received their
health insurance through CVS Caremark and whether their annual household income was at least $60,000 or less than $60,000. I bars indicate 95%
confidence intervals.

pants, the trial measured the specific contributions of acceptance and efficacy of the interventions to their overall effectiveness. This trial also
compared multiple incentive programs with design features based on behavioral economic
theory, including repeated payments to reinforce
target behaviors,43 bonus payments at the end of
the intervention to offset smokers’ tendencies to
discount the importance of future events,44,45 and
the provision of ongoing feedback regarding
participants’ accrued gains and losses contingent on their self-reported smoking status to
maximize the effect of regret aversion.20,21 Finally, this trial randomly selected participants
for screening cotinine tests to prevent nonsmokers from enrolling. The robustness of our findings in analyses accounting for potential participation of nonsmokers provides strong
evidence regarding the effectiveness of incentives.
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Table 2. Analysis of the Complier Average Treatment Effect of Sustained Abstinence from Smoking at 6 Months.*
Absolute Difference in Rate
of Sustained Abstinence

Comparison of Efficacy

percentage points (95% CI)
Reward-based incentives vs. usual care among participants who would accept
reward incentive

10.7 (6.8 to 14.7)

Deposit-based incentives vs. usual care among participants who would accept
deposit incentive

30.8 (11.0 to 50.6)

Deposit-based incentives† vs. reward-based incentives among participants
who would accept either type of incentive, with the assumption that the
underlying odds of quitting among participants who would accept deposits are greater than the odds of quitting among participants who
would only accept rewards by a factor of
2.71, the lower boundary of the 95% CI of the best estimate

25.8 (16.2 to 34.8)

9.36, the best estimate

13.2 (3.1 to 22.8)

23.12, the upper boundary of the 95% CI of the best estimate

6.4 (−5.7 to 17.4)

*	A detailed explanation of this analysis is provided in the Supplementary Appendix. In brief, this method uses the randomization group as an instrumental variable, thereby providing estimates of the efficacy of interventions among people who accept them. Unlike traditional per-protocol analyses, this approach uses data on all randomly assigned participants and adjusts estimates of efficacy for the selection biases that may arise if participants’ decisions to accept or decline their assigned interventions are related to their underlying odds of smoking cessation.34-36 This analysis assumes
that participants who would accept deposits would have also accepted rewards if rewards had instead been offered.
Estimates are on the additive scale; thus, absolute risk differences are shown with 95% confidence intervals (CIs).
†	The efficacy of deposit contracts is statistically superior to the efficacy of rewards as long as the underlying odds of
quitting among participants who accept deposits are no more than 12.5 times greater than the odds of quitting among
participants who would only accept rewards.

In summary, this trial shows that among
several financial-incentive programs for smoking cessation, rewards for smoking cessation are
more effective overall than are deposit-based
contracts owing to their much higher rate of acceptance. In addition, the efficacy of depositbased contracts among those who use them and
the cost-effectiveness of such contracts for employers suggest that future innovations in emReferences
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